Trial 2N-16-6


A Phase 1b Study of the Selective HDAC6 Inhibitor ACY-241 in Combination With Nivolumab in Patients With Unresectable Non-Small Cell Lung Cancer

Type: Treatment
Phase: Phase I
Status: Not Open (Closed)
Treatments: Chemotherapy: Systemic, Immunotherapy
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Diana Hanna, M.D.
Other Trial Staff:  Alicia Bogardus, Coordinator, Cristina De Leon, R.N., Victoria Amran, D.M., Gina Tse, R.N., Eduardo Mejia, D.M., Laurie De Oliveira, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.